KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
about
Macropinocytosis Exploitation by Cancers and Cancer TherapeuticsDefeat mutant KRAS with synthetic lethality.Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality.Membrane orientation dynamics of lipid-modified small GTPases.Targeting reactive oxygen species in development and progression of pancreatic cancer.Drugging RAS: Know the enemy.The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells.Early Detection of Pancreatic Cancer: The Role of Depression and Anxiety as a Precursor for Disease.Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
P2860
Q28069487-27AB9682-BC09-457F-A31B-6933EE773557Q38837319-779BBE36-16A4-41D4-B26A-6A6A7F9B6F04Q38909404-FC7384BA-4FBC-4BF1-8020-77EDE35BB997Q38974930-79F4D2DB-A657-4DCF-9C32-32F145FEF0C6Q39007517-1E7BF313-6882-4BA2-969E-A68400A053F4Q39182842-E8C2B084-035E-4544-8FEC-00F69C005646Q41347759-A776C4E6-FDC3-47F1-A464-14E5B1404DCEQ45559181-9075B722-66B1-430B-B937-78985C169BF9Q47101598-6F574C11-0AF4-40D4-89FB-8E3CFC22286CQ47137660-C44C6CC3-A267-4258-998A-4611D22B47F8Q47701712-CBDCBCB5-B54F-4000-8ED6-2B68AFDB6740Q49798156-D0CD8E9A-BE12-461C-9913-AAAE5D9D0B25Q49853764-0168E46F-C193-4E77-8EB1-B95DE2CB9937Q52657095-6B846026-7E19-4D78-AD57-6A86254C694EQ52672964-C22B9025-54C0-4F84-AF3B-AB0C5F1797B2Q52677107-1EF1EFD4-40E1-403E-870F-7EC7E5AAF929Q56395210-6BC3D78C-4365-4F37-8E9E-5E7EA0DBE337
P2860
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@ast
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@en
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@nl
type
label
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@ast
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@en
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@nl
prefLabel
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@ast
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@en
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@nl
P2093
P2860
P3181
P356
P1433
P1476
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
@en
P2093
Channing J Der
Kirsten L Bryant
Yuliya Pylayeva-Gupta
P2860
P3181
P356
10.3390/CANCERS8040045
P407
P577
2016-01-01T00:00:00Z